Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.98 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.98 |
| ▸ | CYP19A1 | P11511 | 16/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773485 | 0.99 | ESR1 (1.00) | ESR1ESR2CYP19A1LMNAMAPK1 | |
| SCHEMBL774077 | 0.99 | ESR1 (1.00) | ESR1ESR2CYP19A1LMNAMAPK1 | |
| SCHEMBL2842289 | 0.99 | ESR1 (1.00) | ESR1ESR2CYP19A1LMNAMAPK1 | |
| SCHEMBL18798687 | 0.92 | ESR1 (0.84) | ESR1ESR2CYP19A1LMNAMAPK1 | |
| SCHEMBL773684 | 0.92 | ESR1 (0.84) | ESR1ESR2CYP19A1LMNAMAPK1 | |
| SCHEMBL774922 | 0.89 | ESR1 (0.83) | ESR1ESR2CYP19A1LMNAMAPK1 | |
| SCHEMBL774385 | 0.89 | ESR1 (0.79) | ESR1ESR2CYP19A1LMNAMAPK1 | |
| SCHEMBL20626550 | 0.89 | ESR1 (0.79) | ESR1ESR2CYP19A1LMNAMAPK1 | |
| SCHEMBL12544455 | 0.85 | ESR1 (1.00) | ESR1ESR2CYP19A1LMNAMAPK1 | |
| SCHEMBL771976 | 0.85 | ESR1 (1.00) | ESR1ESR2CYP19A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616477-B1 | 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS ER-BETA AGONISTS | ENDECE LLC (US) | 2016-11-09 | — | — | EP | claimed |
| US-9422324-B2 | 6-substituted demethyl-estradiol derivatives as selective ER-β agonists | ENDECE LLC (US) | 2016-08-23 | — | — | US | claimed |
| US-20140315874-A1 | 6-Substituted Demethyl-Estradiol Derivatives as Selective ER-Beta Agonists | ENDECE, LLC | 2014-10-23 | — | — | US | claimed |
| US-20120071455-A1 | 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS SELECTIVE ER-BETA AGONISTS | ENDECE, LLC | 2012-03-22 | — | — | US | claimed |
| EP-2616477-B1 | 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS ER-BETA AGONISTS | ENDECE LLC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20120071455-A1 | 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS SELECTIVE ER-BETA AGONISTS | ENDECE, LLC | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315874-A1 | 6-Substituted Demethyl-Estradiol Derivatives as Selective ER-Beta Agonists | ESR2, ESR1, ESRRG | ESR1 2/4885ESR2 1/4885CYP19A1 8/4885 |
| US-20120071455-A1 | 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS SELECTIVE ER-BETA AGONISTS | ESR2, ESR1, ESRRG | ESR1 2/4885ESR2 1/4885CYP19A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.